Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613736 | 0.90 | MAPK14 (0.46) | MAPK14TRPM8LMNANOTUMOPRD1 | |
| SCHEMBL3605195 | 0.89 | TRPM8 (0.55) | MAPK14TRPM8LMNANOTUMKDM4E | |
| SCHEMBL3605131 | 0.87 | OPRD1 (0.54) | MAPK14LMNAOPRD1KDM4EALDH1A1 | |
| SCHEMBL3598457 | 0.84 | MAPK14 (0.65) | MAPK14TRPM8PTGS1PTGS2KDM4E | |
| SCHEMBL3609666 | 0.81 | TRPM8 (0.47) | MAPK14TRPM8PTGS2KDM4E | |
| SCHEMBL3601669 | 0.80 | MAPK1 (0.50) | TRPM8LMNAOPRD1KDM4EALDH1A1 | |
| SCHEMBL3602177 | 0.80 | MAPK14 (0.57) | MAPK14PTGS1PTGS2LMNANOTUM | |
| SCHEMBL3606735 | 0.79 | TRPM8 (0.41) | TRPM8KDM4EALDH1A1 | |
| SCHEMBL3601696 | 0.79 | TRPM8 (0.41) | TRPM8LMNA | |
| SCHEMBL8985342 | 0.78 | MAPK14 (0.83) | MAPK14PTGS1PTGS2NOTUMOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835476-B2 | Synthesis of novel antimicrobials | WU FAN (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | WU FAN | 2010-03-25 | — | — | US | disclosed |
| WO-2006092059-A1 | DESIGN AND SYNTHESIS OF NOVEL ANTIMICROBIALS | WU FAN (CA) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | MLX, LPXN, TPX2 | MAPK14 3384/4885TRPM8 2375/4885PTGS1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.